Enoxaparin for the treatment of placenta-derived fetal growth restriction (GROWTH): an open-label multicenter randomized trial
Journal of Thrombosis and Haemostasis · 2026-11 · 24 (11) · 3955-3966
DOI: 10.1016/j.jtha.2026.06.045 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-11. Verfasst von Tiphaine Raia-Barjat und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France; INSERM U1059 SAINBIOSE, Université…. Hauptthemen laut MEDLINE: Enoxaparin, Fetal Growth Retardation, Anticoagulants, Placenta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Ministere de la Sante et des Solidarites.
Abstract (Originalsprache)
BACKGROUND: The effect of low-molecular-weight heparin, administered from the time of diagnosis of fetal growth restriction (FGR), on fetal growth and birthweight remains uncertain. OBJECTIVES: To evaluate whether daily enoxaparin, administered from diagnosis of placenta-derived FGR up to 36 weeks of gestation or delivery, reduces the incidence of newborns with a birthweight below the 10th percentile for gestational age. METHODS: This open-label, randomized, multicenter trial (NCT02672566) included pregnant women with a single fetus (≥22 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France; INSERM U1059 SAINBIOSE, Université Jean Monnet, Saint-Étienne, France.
- INSERM U1059 SAINBIOSE, Université Jean Monnet, Saint-Étienne, France; Department of Clinical Pharmacology, CHU De Saint-Étienne, Saint-Étienne, France. Electronic address: silvy.laporte@chu-st-etienne.fr.
- Department of Gynecology and Obstetrics, Hospices Civils de Lyon - Hôpital Femme Mère Enfant, Lyon, France.
- Department of Gynecology and Obstetrics, Hospices Civils de Lyon - Hôpital de la Croix-Rousse, Lyon, France.
- Department of Gynecology and Obstetrics, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.
- Department of Gynecology and Obstetrics, Centre Hospitalier Universitaire de Brest, Brest, France.
Förderung
- Ministere de la Sante et des Solidarites
Zitieren
APA
Raia-Barjat, T., Laporte, S., Gaucherand, P., Huissoud, C., Gallot, D., Merviel, P., Hoffmann, P., Dupuis, O., Giraud, A., Zufferey, P. J., Rancon, F., Presles, E., & Chauleur, C. (2026). Enoxaparin for the treatment of placenta-derived fetal growth restriction (GROWTH): an open-label multicenter randomized trial. Journal of Thrombosis and Haemostasis, 24(11), 3955-3966. https://doi.org/10.1016/j.jtha.2026.06.045
Vancouver
Raia-Barjat T, Laporte S, Gaucherand P, Huissoud C, Gallot D, Merviel P, et al. Enoxaparin for the treatment of placenta-derived fetal growth restriction (GROWTH): an open-label multicenter randomized trial. Journal of Thrombosis and Haemostasis. 2026;24(11):3955-3966. doi:10.1016/j.jtha.2026.06.045
BibTeX
@article{RaiaBarjat2026,
author = {Raia-Barjat, Tiphaine and Laporte, Silvy and Gaucherand, Pascal and Huissoud, Cyril and Gallot, Denis and Merviel, Philippe and Hoffmann, Pascale and Dupuis, Olivier and Giraud, Antoine and Zufferey, Paul J and Rancon, Florence and Presles, Emilie and Chauleur, Céline},
title = {Enoxaparin for the treatment of placenta-derived fetal growth restriction (GROWTH): an open-label multicenter randomized trial},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {11},
pages = {3955--3966},
doi = {10.1016/j.jtha.2026.06.045}
}
EUVIMED